Curis Yönetim

Yönetim kriter kontrolleri 3/4

Curis CEO'su Jim Dentzer, Sep2018 tarihinde atandı, in görev süresi 6.17 yıldır. in toplam yıllık tazminatı $ 1.66M olup, şirket hissesi ve opsiyonları dahil olmak üzere 38.1% maaş ve 61.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.072% ine doğrudan sahiptir ve bu hisseler $ 25.01K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.3 yıl ve 10.3 yıldır.

Anahtar bilgiler

Jim Dentzer

İcra Kurulu Başkanı

US$1.7m

Toplam tazminat

CEO maaş yüzdesi	38.1%
CEO görev süresi	6.2yrs
CEO sahipliği	0.07%
Yönetim ortalama görev süresi	5.3yrs
Yönetim Kurulu ortalama görev süresi	10.3yrs

Son yönetim güncellemeleri

Recent updates

Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues

Nov 14

Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%

Aug 07

Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet

Aug 05

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 03

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Dec 26

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Aug 18

Curis: Asymmetric Risk And Reward

Jul 17

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Mar 28

Checking In On Curis

Dec 15

Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

Dec 04

We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Aug 29

Curis Inc.: Revisiting CA-4948 After Q2 Update

Aug 25

CEO Tazminat Analizi

Jim Dentzer'un ücretlendirmesi Curis'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$45m
Jun 30 2024	n/a	n/a	-US$48m
Mar 31 2024	n/a	n/a	-US$48m
Dec 31 2023	US$2m	US$634k	-US$47m
Sep 30 2023	n/a	n/a	-US$47m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$3m	US$615k	-US$57m
Sep 30 2022	n/a	n/a	-US$59m
Jun 30 2022	n/a	n/a	-US$57m
Mar 31 2022	n/a	n/a	-US$52m
Dec 31 2021	US$3m	US$590k	-US$45m
Sep 30 2021	n/a	n/a	-US$39m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$2m	US$545k	-US$30m
Sep 30 2020	n/a	n/a	-US$31m
Jun 30 2020	n/a	n/a	-US$31m
Mar 31 2020	n/a	n/a	-US$32m
Dec 31 2019	US$2m	US$510k	-US$32m
Sep 30 2019	n/a	n/a	-US$29m
Jun 30 2019	n/a	n/a	-US$30m
Mar 31 2019	n/a	n/a	-US$32m
Dec 31 2018	US$2m	US$479k	-US$33m
Sep 30 2018	n/a	n/a	-US$35m
Jun 30 2018	n/a	n/a	-US$43m
Mar 31 2018	n/a	n/a	-US$48m
Dec 31 2017	US$2m	US$443k	-US$53m

Tazminat ve Piyasa: Jim 'nin toplam tazminatı ($USD 1.66M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 647.72K ).

Tazminat ve Kazançlar: Jim 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jim Dentzer (57 yo)

6.2yrs

Görev süresi

US$1,662,978

Tazminat

Mr. James E. Dentzer, also known as Jim, serves as Independent Director of Imunon, Inc. since September 2022. He serves as President, Chief Executive Officer & Director since September 24, 2018 and Secreta...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Dentzer	President	6.2yrs	US$1.66m	0.072% $ 25.0k
Diantha Duvall	CFO and Principal Financial & Accounting Officer	2.3yrs	US$1.01m	0.0076% $ 2.6k
Jonathan Zung	Chief Development Officer	1.5yrs	US$1.04m	0% $ 0
Mark Noel	Vice President of Technology Management & Intellectual Property	16.2yrs	US$413.39k	Veri yok
Robert Martell	Chief Scientific Officer	no data	US$1.17m	Veri yok
Elif McDonald	VP of Investor Relations & Corporate Communications	no data	Veri yok	Veri yok
Reinhard von Roemeling	Senior Vice President of Clinical Development	5.3yrs	Veri yok	Veri yok

5.3yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: CRIS 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Dentzer	President	6.2yrs	US$1.66m	0.072% $ 25.0k
Martyn Greenacre	Independent Chairman of the Board	24.8yrs	US$158.70k	0.015% $ 5.4k
Marc Rubin	Independent Director	14.4yrs	US$123.70k	0.017% $ 5.9k
Kenneth Kaitin	Independent Director	21yrs	US$126.20k	0.017% $ 5.8k
John Hohneker	Independent Director	2.9yrs	US$106.20k	0% $ 0
Anne Borgman-Hagey	Independent Director	2.1yrs	US$103.70k	0% $ 0

10.3yrs

Ortalama Görev Süresi

66.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CRIS 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.3 yıldır).

Curis Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Curis, Inc., Annual General Meeting, May 21, 2024

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc., Annual General Meeting, May 26, 2022

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues

Curis, Inc. to Report Q3, 2024 Results on Nov 14, 2024

New minor risk - Shareholder dilution

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $12.099999 million.

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $12.099999 million.

Price target decreased by 9.1% to US$22.50

New minor risk - Share price stability

Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%

Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet

New major risk - Negative shareholders equity

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 14%

Curis, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Curis, Inc. Announces Additional Data from Take Aim Leukemia Study

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Curis, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target decreased by 22% to US$77.40

Curis, Inc., Annual General Meeting, May 21, 2024

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Consensus EPS estimates upgraded to US$6.06 loss

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 28%, EPS downgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study

New major risk - Share price stability

Price target increased by 18% to US$180

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2023 Results on Aug 03, 2023

U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Price target increased to US$15.33

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$12.25

Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia Study

FDA Lifts Partial Clinical Hold on the Takeaim Lymphoma Study of Emavusertib of Curis, Inc

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Price target increased to US$17.67

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Curis: Asymmetric Risk And Reward

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc.(NasdaqGM:CRIS) dropped from Russell 3000E Growth Index

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

Consensus EPS estimates fall by 14%

Price target increased to US$15.75

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$14.20

Curis, Inc., Annual General Meeting, May 26, 2022

Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 Study